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Background: The complexity of protein glycosylation makes it difficult to characterize glycosylation patterns on a
proteomic scale. In this study, we developed an integrated strategy for comparatively analyzing N-glycosylation/
glycoproteins quantitatively from complex biological samples in a high-throughput manner. This strategy entailed
separating and enriching glycopeptides/glycoproteins using lectin affinity chromatography, and then tandem
labeling them with 18O/16O to generate a mass shift of 6 Da between the paired glycopeptides, and finally
analyzing them with liquid chromatography-mass spectrometry (LC-MS) and the automatic quantitative method we
developed based on Mascot Distiller.
Results: The accuracy and repeatability of this strategy were first verified using standard glycoproteins; linearity was
maintained within a range of 1:10–10:1. The peptide concentration ratios obtained by the self-build quantitative
method were similar to both the manually calculated and theoretical values, with a standard deviation (SD) of
0.023–0.186 for glycopeptides. The feasibility of the strategy was further confirmed with serum from hepatocellular
carcinoma (HCC) patients and healthy individuals; the expression of 44 glycopeptides and 30 glycoproteins were
significantly different between HCC patient and control serum.
Conclusions: This strategy is accurate, repeatable, and efficient, and may be a useful tool for identification of
disease-related N-glycosylation/glycoprotein changes.
Keywords: 18O labeling, Hepatocellular carcinoma, Mass spectrometry, N-glycoproteomeBackground
The glycosylation of proteins is a common post-
translational modification. The occupancy of the glycosyla-
tion site and the glycan structure in the glycoproteins have
a profound effect on their biological functions [1]. Alter-
ation of this glycosylation influences growth, differentiation,
transformation, adhesion, metastasis, and immune surveil-
lance of cancers [2-6]. Glycans are classified as either
O-linked (through Ser or Thr) or N-linked (through Asn
on the Asn-X-Thr/Ser recognition sequence, X ≠ P) de-
pending on their polypeptide attachment site. In particular,
N-linked glycosylation is prevalent in secreted proteins
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stated.plays a significant role in cellular recognition and signal
transduction and can therefore be considered a potential
therapeutic target or biomarker for diseases, including can-
cers [8,9].
Currently, the most effective and accurate method of
quantitatively analyzing glycopeptides and glycoproteins
is mass spectrometry (MS). MS is usually combined with
other techniques such as various protein/peptide enrich-
ment, labeling, and data analysis techniques to obtain a
complete understanding of protein glycosylation patterns
(including glycosylation sites), site occupancy, and gly-
can structures. However, accurate, quantitative, high-
throughput techniques for comprehensive analyses of
protein glycosylation in complex biological samples have
only rarely been established [8,10].
N-glycosylated sites in a glycopeptide are usually la-
beled and identified with 18O. Kuster et al. reported a
method in which N-linked glycans were enzymaticallytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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(PNGase-F), and the glycosylated Asn residues labeled
with 18O. They demonstrated that the process generated
a mass shift of 2 Da and the glycosylated sites were sub-
sequently identified accurately via MS [11]. Kaji et al.
further modified this method, performing quantitative
comparative analyses using 16O-labeled residues as a
control. However, the partial overlap in isotopic distribu-
tion of the 16O- and 18O-labeled peptides affects the ac-
curacy of this quantitative method [12]. Recently, Liu
et al. established the tandem 18O stable isotope labeling
technique, which includes enriching glycopeptides via
hydrophilic affinity extraction and labeling three 18O or
16O tandems at their C-terminus and N-glycosylation
sites. The mass shift between paired 18O- and 16O-la-
beled glycopeptides is 6 Da [13]. This method overcomes
isotope distribution overlap and enhances the accuracy
of quantification. However, these 18O labeling-related
techniques are time-consuming and low-throughput due
to a lack of software for automatic quantitative analysis
[13], particularly when analyzing a large number of com-
plex biological samples. Moreover, these methods are
not able to identify glycan structure alterations in spe-
cific glycoproteins, which are important for understand-
ing the effects of glycan changes in glycoproteins on
pathological processes.
Lectin affinity chromatography is an accurate glycan
separation technology, and is extensively used to ex-
pound upon the glycan structure in glycoproteins
[14,15]. For example, using this technique, Lens culinaris
(LCH)-affinitive alpha-fetoprotein (AFP-L3) is separated,
which is more accurate in diagnosing liver cancer than
total AFP [16-19]. In the present study, we combined
lectin affinity chromatography, tandem 18O/16O labeling,
MS, and a self-build automatic quantitative method
based on Mascot Distiller software to develop an inte-
grated strategy for high-throughput quantitative analysis
of N-glycosylation changes in complex biological sam-
ples. The accuracy and repeatability of this strategy were
verified using glycoprotein standards. We also utilized
this strategy to analyze the serum of healthy individuals
and hepatocellular carcinoma (HCC) patients to confirm
its feasibility in complex biological samples.
Results and discussion
An integrated strategy for glycoproteomic study
It is well known that protein glycosylation varies widely
between different glycoproteins; indeed, a single glyco-
protein can be glycosylated at multiple sites with
various glycans. Such complexity makes it difficult to
characterize protein glycosylation patterns on a prote-
omic scale. The major limitations of the current glyco-
proteomic studies include: (1) Searching for changes in
glycan structure or glycosylation site occupancy of asingle glycoprotein, rather than in a high-throughput
manner on a large proteomic scale [16,20]; (2) Investi-
gating glycosyltransferase or the general changing trends
of glycan structure in biological samples, regardless
of the glycan structure of each specific glycoprotein
[21-23]; and (3) Analyzing the expression levels of
glycoproteins with specific glycan structure, but not
describing the glycosylation sites and glycosylation site oc-
cupancy [24-27]. In order to overcome these limitations,
we developed an integrated strategy which can be used to
quantitatively analyze the abundance of glycoproteins/gly-
copeptides in a high-throughput manner, as well as the
glycan structure and sites of altered N-glycosylation.
Our overall experimental strategy is shown in Figure 1.
The glycopeptides with specific glycan structure were
enriched via digestion and lectin affinity chromatog-
raphy, and then treated with immobilized trypsin and
PNGase-F in 16O or 18O water. During this process, the
C terminus of the peptide was labeled by two 18O or
16O, and the N-glycosylation site was labeled by one 18O
or 16O. Thus, when they were mixed at the same ratio, a
mass shift of 6 Da was generated between the paired
18O- and 16O-labeled glycopeptides, while only a mass
shift of 4 Da was present between the paired non-
glycopeptides, which could subsequently be identified by
MS. A detailed description of 18O labeling is supplied
in Additional file 1. The relative concentration ratio
could be directly quantitated through the relative signal
strength of the peptide ion pair in the precursor scan be-
cause corrections for the overlapping distributions of
monoisotopic peaks were built into the software.
The glycan structure of glycoproteins is specifically
recognized by lectin and the glycan structure changes of
glycoproteins distinguished by LCH, WGA, or ConA are
associated with cancer development, and therefore have po-
tential diagnostic and prognostic values [28-31]. As such, in
this study, we used LCH, WGA, and ConA lectin chroma-
tography to separate and enrich glycopeptides with a spe-
cific glycan structure. Using this method, we were able to
obtain information regarding changes in the abundance of
glycoproteins with different types of glycan, as well as the
glycosylation site and glycosylation site occupancy in each
altered glycoprotein, all with one experiment. Our strategy
pinpoints the glycosylation changes to each glycoprotein on
a large glycoproteomics scale, providing a valuable supple-
ment to techniques currently used in glycoproteomics.
However, lectin affinity chromatography is far from ideal
[32-34], as the enrichment efficiency of the method is un-
satisfactory, is easily affected by buffer conditions, and non-
specifically recognizes glycans [35,36]. In this study, we
attempted to stabilize the binding and elution buffers,
including adjustment of pH, concentration, and binding/
eluting time, in different experiments, to overcome these
disadvantages.
Figure 1 Flow chart of the integrated strategy. Serum samples were digested with trypsin after removal of high-abundance proteins. Glycopeptides
were enriched with lectin chromatography from two different samples, desalted, and then catalyzed by immobilized trypsin and PNGase-F in 18O or 16O
water, as indicated. Equal amounts of 18O- and 16O-labeled glycopeptides were mixed, and the 6 Da mass shifts were generated between paired, labeled
glycopeptides, which could be identified by subsequent LC-ESI-MS/MS. The data were quantitatively analyzed automatically with the
self-build quantitative method.
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primarily due to the reversible labeling reaction at the
C-terminus [37]. A number of factors may affect the
efficiency of 18O labeling at the C-terminus, such as
the catalytic activity of trypsin, the purity of H2
18O,
H2
16O, and other reagents, the back-exchange caused
by incomplete trypsin quenching, and the relative posi-
tions of Lys and Asp/Glu at the C-terminus [38-40]. In
order to remove these interference factors, we made
the following modifications to our experiments based
on previous studies: (1) Immobilized trypsin was ap-
plied to increase the mole ratio of protease to substrate
and improve labeling efficiency [41]. The immobilized
enzymes could be completely removed physically after
the reaction and the carboxyl oxygen exchange nearly
ceased and reduced back-exchange; (2) Acidic condi-
tions were adopted to facilitate catalysis of the carboxyl
oxygen reaction and obtain better efficiency of the
immobilized trypsin labeling [40,42]; and (3) After di-
gestion with trypsin, samples were boiled for 10 min
followed by freezing for 5 min, and methanoic acid was
added prior to PNGase-F labeling to fully quench the
trypsin and avoid back-exchange [39].
Validation of the feasibility and accuracy of the
integrative strategy
The glycoproteins invertase and Fetuin were used as
standards to evaluate the accuracy and feasibility of thisintegrated strategy for quantitation of N-glycoproteins.
The glycopeptides were enriched from the glycoprotein
standards with ConA lectin chromatography, and labeled
with 18O and 16O. The 18O- and 16O-labeled glycopep-
tides were mixed in ratios of 1:1, 1:2, 2:1, 1:5, 5:1, 1:10,
and 10:1, then analyzed by LC-MS. The relative concen-
tration ratios of the glycopeptides (18O3/
16O3) were cal-
culated using Formula 1, and the relative concentration
ratios of the non-glycopeptides (18O2/
16O2) were calcu-
lated according to Formula 2 (see details in the methods
section). In the mass spectrum of the mixed glycopep-
tides, the mass shift of 6 Da was easily identified
for paired glycopeptides, and the mass shift of 4 Da
was identified for paired non-glycopeptides (Additional
file 2), accurately distinguishing between the two. Four
glycopeptides and four non-glycopeptides in invertase
and Fetuin were selected to further manually calculate
relative concentration ratios. We found that peptide
concentration ratios from manual calculation were simi-
lar to theoretical values (Table 1), and correlation coeffi-
cients (R2) were all >0.99 (Figure 2). These results
indicated that our strategy had good linearity and accur-
acy in a 100-fold dynamic range.
Confirmation of the precision of the self-build method
Although data analysis of some 18O labeling methods
can be supported by some automatic software, the tan-
dem 18O3 labeling technique lacks matched software,
Table 1 Relative abundance ratios of the 18O/16O-labeled glycopeptides and non-glycopeptides in glycoprotein
standards
Protein Peptide sequence Expected ratio (Sample A:B) Manually calculated ratio Self-build quantitative method ratio
Invertase FATN*TTLTK 1 (1:1) 0.961 0.897
2 (2:1) 1.997 1.982
5 (5:1) 4.880 4.856
0.5 (1:2) 0.563 0.491
0.2 (1:5) 0.236 0.188
0.1 (1:10) 0.129 0.104
10 (10:1) 9.989 9.456
LMTN*ETSDRPLVHFTPNK 1 (1:1) 0.992 0.953
2 (2:1) 2.169 1.939
5 (5:1) 4.980 5.033
0.5 (1:2) 0.567 0.517
0.2 (1:5) 0.216 0.192
0.1 (1:10) 0.103 0.089
10 (10:1) 10.110 10.050
ENPYFTNR 1 (1:1) 0.937 0.997
2 (2:1) 2.040 2.144
5 (5:1) 5.217 5.462
0.5 (1:2) 0.474 0.539
0.2 (1:5) 0.177 0.208
0.1 (1:10) 0.085 0.111
10 (10:1) 10.558 11.160
GLEDPEEYLR 1 (1:1) 0.769 0.837
2 (2:1) 1.714 1.788
5 (5:1) 5.014 4.437
0.5 (1:2) 0.472 0.458
0.2 (1:5) 0.184 0.183
0.1 (1:10) 0.084 0.086
10 (10:1) 9.636 11.110
Fetuin AESN*GSYLQLVEISR 1 (1:1) 1.138 0.886
2 (2:1) 1.735 1.588
5 (5:1) 4.664 5.070
0.5 (1:2) 0.562 0.424
0.2 (1:5) 0.219 0.143
0.1 (1:10) 0.075 0.036
10 (10:1) 9.849 12.330
LAPLN*DSR 1 (1:1) 0.980 0.965
2 (2:1) 1.797 1.824
5 (5:1) 4.627 4.174
0.5 (1:2) 0.397 0.415
0.2 (1:5) 0.158 0.184
0.1 (1:10) 0.096 0.103
10 (10:1) 11.289 Na
ALGGEDVR 1 (1:1) 0.904 0.969
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Table 1 Relative abundance ratios of the 18O/16O-labeled glycopeptides and non-glycopeptides in glycoprotein
standards (Continued)
2 (2:1) 2.116 1.913
5 (5:1) 5.748 4.589
0.5 (1:2) 0.469 0.471
0.2 (1:5) 0.175 0.170
0.1 (1:10) 0.088 0.080
10 (10:1) 12.237 11.540
TPIVGQPSIPGGPVR 1 (1:1) 1.067 1.042
2 (2:1) 2.102 1.986
5 (5:1) 5.823 5.559
0.5 (1:2) 0.460 0.479
0.2 (1:5) 0.183 0.163
0.1 (1:10) 0.063 0.100
10 (10:1) 10.414 10.120
*Denotes the N-glycosylation site.
aself-build quantitative method did not give a ratio.
Sample A was treated in 18O water and Sample B in 16O water. N = self-build quantitative method did not give a ratio.
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time-consuming manual calculation. Managing data
from complex biological samples using manual calcula-
tion is difficult, necessitating an accurate, reliable, and
user-friendly automated analysis method for data gen-
erated with 18O3 labeling [13]. In our study, two cus-
tomized software packages, XPRESS and ASAPRatio,
including the Trans-Proteomic Pipeline Ver. 4.5 (TPP,
Seattle Proteome Center), were first used to quantita-
tively analyze data generated from the 18O3-labeled
glycoprotein standards. The results were disappoint-
ing; XPRESS gave linear results to non-glycopeptides
labeled with 18O2, rather than to the
18O3-labeled gly-
copeptides, and the quantitative results generated by
ASAPRatio were even less satisfactory than those of
XPRESS (Additional file 3). We established an auto-
matic quantitative method for the 18O3 labeling tech-
nique based on Mascot Distiller and applied it to
analyze the glycoprotein standard data obtained from
LC-MS. As shown in Table 1, the peptide concentra-
tion ratios calculated by this quantitative method were
similar to both the theoretical values and the manually
calculated results, and had good linearity and accuracy
within the ratio range of 1:10–10:1 (Table 1 and
Figure 2). Similar results were found with the protein
concentration ratios (Figure 3). These data indicate
that this quantitative method is reliable for calculating
concentration ratios of both peptides and proteins la-
beled with 18O3, and may replace the time-consuming
manual calculation in time.
As mentioned in the methods section, three modifica-
tion groups were defined in the self-build quantitativemethod, and the quantitative ratio of 18O/16O was finally
generated via Formula 3 [(Group A + Group B)/Group
C] to avoid the influences of back-exchange and incom-
plete C-terminal labeling on the final result. The ratio of
Group A to Group C was used to evaluate the influences
of back-exchange and incomplete C-terminal labeling.
We found that if these influencing factors had not been
excluded, the final quantitative ratios of 18O3/
16O3 dif-
fered from the theoretical ones (Figure 3), demonstrating
that even the labeling efficiency was improved in this
study. These data indicate that the quantitative setting in
our study is correct and can minimize the influence of
incomplete labeling and back-exchange of 18O.
Establishment of the quantitative criteria for this
integrative strategy
In order to establish the measurement criteria for the
relative quantification of glycoproteins and glycopep-
tides, the 16O/18O-labeled glycoprotein standard mixture
at a ratio of 1:1 was repeatedly analyzed by LC-MS and
quantitatively calculated seven times. The SD was de-
tected in the spectrum of the glycoprotein standard, with
a SD range of 0.023–0.186 for the glycopeptide and
0.075–0.216 for the glycoprotein. The relative quantita-
tive ratios generated are listed in Table 2. An 16O/18O-
labeled glycopeptide or glycoprotein ratio >3 times the
SD value was considered a significant change; in con-
trast, when the ratio was within 1–3 times the SD, it was
considered a minor change [13,43]. Thus, the quantita-
tive criteria were defined as follows: Significant changes
were determined when the ratio was smaller than 0.63
or greater than 1.57 for glycopeptides and less than 0.60
Figure 2 Linearity and accuracy of the self-build quantitative method in glycopeptides from glycoprotein standards. Four glycopeptides,
FATN*TTLTK and LMTN*ETSDRPLVHFTPNK from invertase [Swiss-Prot:P00724] and AESN*GSYLQLVEISR and LAPLN*DSR from Fetuin [Swiss-Prot:
P12763], were serially diluted to determine the linearity and accuracy of the self-build quantitative method. On the left are the results from
manual calculation and on the right are the results from the self-build quantitative method. Glycopeptide concentration ratios calculated manually
and those from the self-build method were all significantly associated with the theoretical values, with both correlation coefficients (R2) being >0.99.
*denotes the N-glycosylation site.
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were assumed when the ratio was 0.63–0.84 or 1.19–
1.57 for glycopeptides and 0.60–0.82 or 1.22–1.65 for
glycoproteins.Validation of the feasibility of the integrative strategy in
complex biological samples
Serum samples from three HCC patients and three
healthy individuals were used to determine the feasibility
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that gender and age may partially affect serum glycan
distributions and a number of environmental variables
(such as smoking) may also be associated with serum
glycome components [44-46], we matched the HCC pa-
tients and healthy individuals as much as possible to de-
crease bias caused by individual differences.
The glycopeptides in the serum samples were sepa-
rated and enriched with ConA, LCH, or WGA lectin
chromatography, generating three subgroups of glyco-
peptides specifically recognized by ConA, LCH, and
WGA, respectively. The glycopeptides were then labeled
with 18O or 16O, followed by mixing the glycopeptides in
a ratio of 1:1 from each subgroup of glycopeptides. Each
mixture was repeatedly analyzed by LC-MS and quanti-
tatively calculated seven times. We found that 44 uniqueFigure 3 Linearity and accuracy of the self-build quantitative method
invertase were serially diluted to determine the linearity and accuracy of th
Group C. Glycopeptide concentration ratios calculated by the self-build me
both correlation coefficients (R2) being >0.99. (B) The ratio of Group A/G
incomplete labeling in glycoprotein standards; a difference was found b
(B) and the theoretical ratio.glycopeptides and 30 glycoproteins with a specific glycan
structure were differently expressed between HCC pa-
tients and healthy individuals (Additional file 4). Among
these differentially expressed glycopeptides and glyco-
proteins, 14 and 13 changed in more than one lectin
subgroup, respectively (see detailed data in Additional
files 5 and 6). There were 67 unchanged glycopeptides in
serum samples (see detailed data in Additional file 7).
All N-linked glycopeptides had a consensus motif of
Asn-X-Thr/Ser (X ≠ P). However, there were very low
amounts of the differentially expressed glycopeptides/
glycoproteins identified in our study, partially due to the
limited volume of the serum samples and the multi-step
processing of samples. All detailed data of detected gly-
copeptides in HCC patient and health control serum is
shown in Additional file 8.for glycoprotein standards. The glycoprotein standards Fetuin and
e self-build quantitative method. (A) The ratio of (Group A + Group B)/
thod were significantly associated with the theoretical values, with
roup C was calculated without considering back-labeling and
etween the result of the relative quantitation ratio of 18O/16O in
Table 2 The SD for glycoproteins and four glycopeptides
from ConA-enriched Fetuin and invertase in a 1:1 18O/16O
ratio calculated by the self-build quantitative method







*denotes the N-glycosylation site.
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clusterin (CLUS) protein glycopeptide, LAN*LTQGED-
QYYLR, in the ConA subgroup is shown in Figure 4;
Figure 4A shows a magnified MS spectrum with a
monoisotopic peak of double-charged peptide at m/z
845.91943 (18O) and 842.91333 (16O), representing a
6 Da mass shift. The MS spectrum indicated that there
were three 18O atom labels and a mono-glycosylation
site on this glycopeptide. The fragmented ion MS/MS
spectrum had a mass shift of 117 Da between the y11
and y12 ions, equal to the mass shift generated by aspar-
tic acid after being labeled by one 18O atom, and character-
istically verified the deamidation of Asn in this position.
The mass shift of 4 Da was displayed in all singly charged y
ions (Figure 4B and C), indicating that the C-terminus was
labeled by two 18O. A 2-Da mass shift was displayed in the
b-ion series of monocharges, confirming that one 18O was
present at the monoglycosylation site (Asn residue).
The quantitative results of the serum samples were
verified again by manual calculation of the four selected
glycopeptides. There was no significant difference between
the automatically quantitated ratios and the manually
calculated ones (Additional file 9), suggesting that this auto-
matic quantitative method is reliable for analysis of com-
plex biological samples.
Compared with the healthy individuals, the alterations
of some glycopeptide/glycoprotein levels in HCC pa-
tients were inconsistent, even converse, among the three
subgroups of glycopeptides (Figure 5). These data sug-
gest that the glycan structure on specific glycosylation
sites may also be altered in these glycoproteins. Com-
pared with the studies using total serum or tissue glyco-
proteome, glycoprotein subgroups separated by lectin
chromatography could reduce the complexity of tested
samples and improve the detection of low-abundance
proteins. Therefore, these glycan changes on specific gly-
coproteins may be sensitive potential biomarkers for dis-
ease diagnosis, which are worthy of further investigation.
Among these proteins, apolipoprotein D (APOD) was
down-regulated in HCC patient serum in all three lectin
subgroups, and CLUS was up-regulated in all threelectin subgroups, consistent with previous data [47,48].
To further validate the quantitative results obtained by
our strategy, we determined the expression levels of
glycoprotein LG3BP by western blot in the ConA and
LCH lectin subgroups from HCC patient and healthy in-
dividual serum. As shown in Figure 6, the band intensity
ratio of HCC patients versus healthy individuals was
1.66 in the ConA subgroup and 0.66 in the LCH sub-
group. These were very similar to the ratios of glycopro-
teins (1.32 in the ConA subgroup and 0.61 in the LCH
subgroup) and glycopeptide ratios of the proteins (1.64
in the ConA subgroup and 0.61 in the LCH subgroup)
obtained by our integrated strategy. The quantity
changes observed in the integrated strategy were inde-
pendently confirmed by western blot. These differentially
expressed glycoproteins might play an important role in
screening for sporadic HCC in the general population.
All of the above results indicate that the present labeling
strategy is feasible and reliable.
Conclusions
In this study, we established an integrated research strat-
egy for the high-throughput, quantitative analysis of N-
linked glycoproteomics. This strategy integrated lectin
chromatography and tandem 18O/16O labeling with LC-
MS analysis and our novel automatic data analysis
method. We also made modifications to the techniques
used to avoid various interferences and enhance the la-
beling efficiency of 18O3. We demonstrated this strategy
to be accurate and reliable using glycoprotein standards,
and then identified a number of N-glycoproteins with
specific glycan structures that were differently expressed
between HCC patients and healthy individuals, as well
as N-glycoproteins with modified glycosylation site oc-
cupancy. Western blot analysis further confirmed these
results. This integrated strategy provides a useful tool
for identifying disease-related N-glycosylation changes




The ProteoMiner Protein Enrichment Kit was purchased
from Bio-Rad (Hercules, CA), the PNGase-F from New
England BioLabs (Ipswich, MA), the C18 cartridge from
Waters (Milford, MA), the 3-kDa spin column from
Millipore (Billerica, MA), and the immobilized trypsin
beads from Applied Biosystems (Framingham, MA). The
concanavalin A (ConA)-based and wheat germ agglutinin
(WGA)-based glycoprotein isolation kit, the bicinchoninic
acid (BCA) assay kit and MicroSpin column were obtained
from Pierce (Rockford, IL). The LCH-based isolation kit
was from GALAB (Germany). The glycoprotein standards
(bovine Fetuin and yeast invertase), 18O water (97%), and
Figure 4 (See legend on next page.)
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Figure 4 MS and quantitation of a deglycosylated peptide, LAN*LTQGEDQYYLR, from ConA-enriched CLUS [Swiss-Prot: P10909] glycoprotein
in human serum. (A) Double-charged peptide labeled with 18O and 16O. The m/z 845.91943 (18O) and 842.91333 (16O) displays a 6 Da mass shift in the
monoisotopic peaks; the intensity ratio of the 18O/16O isotope cluster was 1.812. (B) Mass spectrum of the glycopeptide labeled with 18O in m/z 845.91943.
(C) Mass spectrum of the glycopeptide labeled with 16O in m/z 842.91333. *denotes the N-glycosylation site.
Figure 5 Glycopeptides/glycoproteins with inconsistent changes in the ConA, LCH, and WGA subgroups. (A) When comparing HCC
patients with healthy individuals, five glycoproteins were altered inconsistently among the three lectin subgroups (ConA, LCH, and WGA); (B)
When comparing the serum of HCC patients with that of healthy individuals, six glycopeptides changed discordantly among the three lectin
subgroups (ConA, LCH, and WGA). Each column represents the percentage of the amount of glycopeptide/glycoprotein (HCC patients versus
healthy individuals) in each lectin subgroup. Positive percentages denote upregulation, whereas negative percentages denote downregulation.
Glycopeptide GLN*VTLSSTGR was from CO4A_HUMAN [Swiss-Prot:P0C0L4], LAN*LTQGEDQYYLR from CLUS_HUMAN [Swiss-Prot:P10909],
ADGTVNQIEGEATPVN*LTEPAK from APOD_HUMAN [Swiss-Prot:P05090], ALGFEN*ATQALGR from LG3BP_HUMAN [Swiss-Prot:Q08380],
SVTWSESGQN*VTAR from IGHA2_HUMAN [Swiss-Prot:P01877], and FSDGLESN*SSTQFEVK from CO4B_HUMAN [Swiss-Prot:P0C0L5]. Other
glycoproteins were MUCB_HUMAN [Swiss-Prot:P04220] and VTNC_HUMAN [Swiss-Prot:P04004]. *denotes the N-glycosylation site.
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Figure 6 (See legend on next page.)
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Figure 6 Validation of glycoprotein LG3BP in different lectin subgroups by western blot. (A) The expression levels of LG3BP in ConA and
LCH lectin subgroups from the serum of HCC patients and healthy individuals were detected by western blot. (B) The target band intensities
were quantified by ImageQuantTL software. The band intensity ratio of HCC patients versus healthy individuals was 1.66 in the ConA
subgroup and 0.66 in the LCH subgroup. (C) The mass spectrum of a glycopeptide, ALGFEN*ATQALGR, from glycoprotein LG3BP in the
ConA subgroups. (D) The mass spectrum of the glycopeptide, ALGFEN*ATQALGR, from glycoprotein LG3BP in the LCH subgroups. The 18O/
16O ratios (HCC patients versus healthy individuals) of these glycopeptides were 1.64 in the ConA subgroup and 0.61 in the LCH subgroup.
*denotes the N-glycosylation site.
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Louis, MO).
Preparation of serum samples
The archived serum samples of patients with HCC were
obtained from Zhongshan Hospital, Fudan University
(Shanghai, China). Healthy individuals served as normal
controls. Physiological conditions such as age, etc., were
matched to decrease bias caused by individual differ-
ences. Detailed information regarding the HCC patients
and controls were summarized in Additional file 10. This
study was approved by the Research Ethics Committee of
Zhongshan Hospital, and informed consent was obtained
from all subjects.
The serum samples were stored at −80°C before pro-
cessing. Equal volumes of serum from three HCC pa-
tients or three healthy individuals were pooled together
to generate two sample pools, which were used in subse-
quent experiments. The most abundant serum proteins
were removed by the ProteoMiner Protein Enrichment
Kit according to the manufacturer's instruction. The pro-
tein concentrations were determined using the BCA assay
kit.
Digestion of glycoprotein standards and serum samples
The paired serum samples and the glycoprotein stan-
dards, Fetuin and yeast invertase, in solution were dena-
tured at 100°C for 10 min. The samples were reduced
with 10 mM dithiothreitol (DTT) at 57°C for 30 min
and alkylated with 30 mM iodoacetamide at room
temperature for 1 h in the dark. After desalting by spin
column, the samples were digested with trypsin at an
enzyme-to-substrate ratio of 1:50 (w/w) at 37°C for 16 h.
To quench the trypsin and prevent back-exchange of
18O, the digested samples were boiled in a water bath
for 10 min and then placed on ice for 5 min, as previ-
ously described [39].
Lectin affinity chromatography
Lectin affinity chromatography was performed using
ConA-, LCH-, and WGA-based isolation kits to separate
out glycopeptides with specific glycan structure. Briefly,
the digested serum samples or glycoprotein standards
were diluted with binding/wash buffer and then added
to the resin bed and incubated for 10 min at roomtemperature. The resin was then washed and the bound
glycopeptides eluted and collected.
Isotope labeling with 18O or 16O water
After lectin affinity chromatography, the peptides ob-
tained from the samples and glycoprotein standards
were desalted using SepPak C18 cartridges, and then
dried in a vacuum centrifuge. The peptides were then
mixed with immobilized trypsin (20% slurry v/w) for
20 min with gentle shaking, and then lyophilized. The
lyophilized peptides were dissolved in 100 μL aceto-
nitrile in 50 mM NH4HCO3 (pH 6.8) (ACN/NH4HCO3,
20% v/v) prepared with H2
16O or H2
18O in advance, then
incubated at 37°C for 24 h to catalyze the labeling of
tryptic peptides at the C-terminus. The immobilized
trypsin beads were then removed by MicroSpin columns.
A total of 5 μL formic acid was added to further inhibit
any possible residual trypsin activity. The peptides were
lyophilized and then dissolved in 100 mM NH4HCO3
buffer prepared in H2
16O or H2
18O. PNGase F was added
at a concentration of 1 μL PNGase-F/mg of crude pro-
tein, and the labeling was conducted at 37°C overnight.
Finally, the 16O- and 18O-labeled peptides were mixed at
designated ratios (1:1, 2:1, 1:2, 5:1, 1:5, 10:1, and 1:10 for
glycoprotein standards; 1:1 for samples) and lyophilized.
Nano LC-electrospray ionization (ESI)-MS/MS
The lyophilized peptides were resuspended with 2%
ACN in 0.1% formic acid, separated by nano LC, and
then analyzed by online electrospray tandem mass
spectrometry. The experiments were performed on a
Nano Aquity UPLC system (Waters) connected to an
LTQ Orbitrap XL mass spectrometer (Thermo Electron
Corp., Bremen, Germany) interfaced with an online nano
electrospray ion source (Michrom Bioresources, Auburn,
CA). The peptide separation was performed in a
Michrom CAPTRAP (500 μm i.d. × 2 mm trap column)
and a Michrom C18 (3.5 μm, 100 μm i.d. × 15 cm reverse
phase column) (Michrom Bioresources). The model glyco-
protein digests (0.5 μg) were loaded onto the trap column
and leached at a flow rate of 20 μL/min for 3 min. The mo-
bile phases included 2% ACN in 0.1% formic acid (phase A
and the loading phase) and 95% ACN in 0.1% formic acid
(phase B). To achieve sufficient separation, a 60-min (for
glycoprotein standards) or 90-min (for serum samples)
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The flow rate of the mobile phase was set at 500 nL/min,
and the electrospray voltage used was 1.6 kV. The linear
gradient was adjusted to 90 min for serum samples ana-
lyses, while all other parameters remained unchanged. The
LTQ Orbitrap XL mass spectrometer was operated in the
data-dependent mode with an automatic switch between
MS and MS/MS acquisition. The survey full-scan MS spec-
tra with two microscans (m/z 350–1800) was acquired in
Orbitrap at a resolution of 100,000 (at m/z 400) followed
by eight MS/MS scans in LTQ trap. Dynamic exclusion
was set to initiate a 60 s exclusion for ions analyzed twice
within a 10 s interval.
Manual calculation of relative concentration ratios
The mass spectra acquired by Nano LC-ESI-MS/MS of
the samples were searched against the human Inter-
national Protein Index (IPI) database (IPI human v3.45
FASTA with 71,983 entries, with bovine Fetuin and yeast
invertase manually added), using the SEQUEST algorithm
integrated into the Bioworks package (Version 3.3.1;
Thermo Electron). The parameters for the SEQUEST
search included: enzyme, partial trypsin; missed cleavages
allowed, two; fixed modification, carboxyamidomethylation
(Cys); variable modifications, deamidation (Asn +0.98 Da),
deamidation plus 18O (Asn +2.98 Da), C-term (+4.01 Da),
and oxidation (Met +15.99 Da); peptide tolerance, 10 ppm;
and MS/MS tolerance, 1.00 Da. The statistical significance
of the database search results was evaluated with the aid of
PeptideProphet [49]. A minimum PeptideProphet probabil-
ity score (P) filter of 0.9 was selected as a threshold to re-
move low-probability peptides.
The relative concentration ratios of the peptides were
then manually calculated. Formula 1 was used to calcu-







I2 þ I4 þ I6− M2M0
 
I4− M2M0 þ M4M0 − M2M0
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Formula 2 was used to calculate the ratio (16O/18O) of






I2 þ I4− M2M0
 
I2− M2M0 þ M4M0 − M2M0
 2 
I0
M0, M2, M4, and M6 are the corresponding theoretical
relative intensities of the isotopic envelope of the peptide,
calculated using MS-Isotope (http://prospector.ucsf.edu).Calculation of relative concentration ratios with the
self-build quantitative method
The raw data acquired by Nano LC-ESI-MS/MS were
searched against the Swiss-Prot database using the Mascot
Distiller software (Version 2.3.2.0; Matrix Science) and
user-defined search criteria. The search parameters were
set according to the preceding settings of Bioworks. The
relative concentration ratios were generated by the Mascot
Distiller software with a self-build quantitative method.
In this method, the quantitative protocol is the precur-
sor. Taking into account the incomplete label or back-
exchange on the C-terminus, three exclusive modification
groups were used for calculating the ratios: Group A was
comprised of two 18O labels on the C-terminus and one
18O label on each N-glycosylated Asn residue; Group B in-
cluded one 18O label on the C-terminus and one 18O label
on each N-glycosylated Asn residue; and Group C were la-
beled by 16O on both of these sites. As one given peptide
may only carry one or another set of modifications, but
never have a mixture of both sets, the “exclusive” modifi-
cation group was used to avoid interference from the too-
complex resultant data and too many variable modifications
derived from the pooled samples. The isotope and impurity
correction factors were set to 97% 18O based on actual




¼ Group Aþ Group Bð Þ=Group C
The glycoprotein ratios were calculated according to
the median of the glycopeptide ratios with the self-built
quantitation software. Additional file 11 is self-build
quantitation setting file and Additional file 12 is a modi-
fied unimod file.
Western blot
The expression level of glycoprotein galectin-3-binding
protein (LG3BP) was evaluated by western blot to valid-
ate the results of the integrated research strategy.
The glycoproteins in the depleted pooled serum from
three HCC patients and three healthy individuals were
enriched by lectin affinity chromatography, and then
separated by 10% sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE) followed by transfer
onto polyvinylidene fluoride membranes. Anti-LG3BP
(Santa Cruz Biotechnology, Dallas, TX) was used as the
primary antibody. The quantitative signals were ac-
quired and quantified via a LAS-4000 imager and Ima-
geQuantTL software (Version 7.0; GE Healthcare,
Piscataway, NJ).
Statistical evaluation
Based on the statistical three-sigma rule which states
that nearly all values lie within 3 standard deviations
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established a set of criteria for statistical evaluation of
glycopeptide/glycoprotein differences using the glyco-
protein standards. Compared with the controls, a change
of more than 3-fold of SD at an abundance ratio of 1.0
was considered statistically significant at a 99% confi-
dence level [52,53].Additional files
Additional file 1: The reaction of three 18O atoms labeling
happened in the glycopeptides by catalysis with Trypsin and
PNGase F. The reaction is reversible at the 18O labeling of the C-terminal
catalyzed with trypsin, indicating that the back-exchange and C-terminal
single 18O labeling in the C-terminal cannot be completely avoided in
the reaction product. This feature is a problem identified in the experi-
mental operation, result analysis, and quantitative method design, but do
not need to consider in the labeling process of PNGase-F catalysis.
Additional file 2: The mass shifts identified by mass spectrum
between paired 18O and 16O labeled glycopeptides/non-
glycopeptides from standard glycoprotein Invertase. (A) For the non-
glycopeptides VFWYEPSQK, the mass shift of 4 Da was generated in mass
spectrometry. (B) For the glycopeptide FATN*TTLTK, the mass shift of
6 Da was generated in mass spectrometry. *denotes the N-glycosylation
site.
Additional file 3: ASAP and XPRESS ratios of glycopeptides and
non-glycopeptides in the dynamic range of 1:10–10:1 derived by
Trans-Proteomic Pipeline Ver. 4.5.
Additional file 4: The number of differently expressed
glycoproteins/glycopeptides between HCC patients and healthy
individuals in the three lectin subgroups. The data calculated by
self-build quantitative method.
Additional file 5: The table of changed glycopeptides in HCC
patient serum (18O Labeling) compared to health control (16O
Labeling).
Additional file 6: The table of changed glycoproteins in HCC
patient serum (18O Labeling) compared to health control (16O
Labeling).
Additional file 7: The table of unchanged glycopeptides in HCC
patient serum (18O Labeling) compared to health control (16O
Labeling).
Additional file 8: The detailed data of detected glycopeptides in
HCC patient serum (18O Labeling) compared to health control (16O
Labeling).
Additional file 9: Calculation of abundance ratios of four
glycopeptides between HCC patients and healthy individuals. The
ratios calculated manually were similar to the ratios obtained by self-build
quantitative method, which indicated the reliability of the quantitative results
of our integrated research strategy.
Additional file 10: Physiological/pathological characteristics of
patients and healthy individuals enrolled in this study.
Additional file 11: Our self-build quantitation setting file.
Additional file 12: A Modified unimod file. You can download
Additional files 9 and 10, copy them into the directory of /mascot/
config/, please backup the original files before copying.Abbreviations
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